AH Bio Fund II, L.P. bought $5.0M of Scribe Therapeutics (SCTX)
Executed Jul 27, disclosed Jul 29, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Jul 29), the stock returned +75.6% (delay-adjusted); from the execution session (Jul 27), +73.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
AH Bio Fund II, L.P. (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (1 purchase, 1 sale), most often in NAUT. Across 1 priced purchase filing, the average 21-session return was +73.4% from execution and +75.6% from disclosure (delay-adjusted; derived). The largest single filing was $11.8M of NAUT (5,000,000 sh across 2 lots, as filed), executed Jun 2.
Healthcare · Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→